文献速递肿瘤 PET/CT

开发PET/CT分子影像组学-临床模型预测直径≤3 cm浸润性肺腺癌胸部淋巴结转移

Development of a PET/CT molecular radiomics-clinical model to predict thoracic lymph node metastasis of invasive lung adenocarcinoma ≤ 3 cm in diameter.
PubMed 文献 · EJNMMI Res · 2022-04-21

该回顾性研究纳入528例浸润性肺腺癌(≤3 cm)患者,构建PET影像组学、CT影像组学、PET/CT影像组学、临床及整合PET/CT影像组学-临床共5种模型预测胸部淋巴结转移。整合模型预测性能优于临床模型及其他三种影像组学模型,训练组AUC为0.95(95%CI:0.93-0.97),测试组AUC为0.94(95%CI:0.89-0.97),列线图和决策曲线分析证实其临床应用价值。

要点

  • 整合PET/CT影像组学-临床模型预测胸部淋巴结转移的AUC在训练组为0.95、测试组为0.94。
  • 整合模型预测性能优于单独临床模型及PET、CT、PET/CT三种影像组学模型。
  • 列线图分析和决策曲线分析证实整合模型具有临床应用价值。

核心结论

  • 整合PET/CT分子影像组学-临床模型在预测临床浸润性肺腺癌(≤3 cm)胸部淋巴结转移方面,较单独影像组学模型或临床模型可保证更高水平的准确性。

研究设计与样本

  • 回顾性研究,共纳入528例肺腺癌患者。
  • 构建了PET影像组学、CT影像组学、PET/CT影像组学、临床及整合PET/CT影像组学-临床共5种模型用于预测胸部淋巴结转移。
  • 整合PET/CT影像组学-临床模型选取10个PET/CT影像组学特征和2个临床特征构建。
  • 采用受试者工作特征(ROC)曲线分析检验所有模型的预测性能,并通过列线图分析和决策曲线分析(DCA)验证临床效用。

主要发现

  • 根据ROC曲线分析,整合PET/CT分子影像组学-临床模型优于临床模型和其他三种影像组学模型。
  • 整合模型AUC在训练组为0.95(95%CI:0.93-0.97),在测试组为0.94(95%CI:0.89-0.97)。
  • 列线图分析和DCA证实该整合模型在预测胸部淋巴结转移方面具有临床应用价值。

关键数值与推荐

  • 整合PET/CT影像组学-临床模型训练组AUC为0.95(95%CI:0.93-0.97)。
  • 整合PET/CT影像组学-临床模型测试组AUC为0.94(95%CI:0.89-0.97)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To investigate the value of 18F-FDG PET/CT molecular radiomics combined with a clinical model in predicting thoracic lymph node metastasis (LNM) in invasive lung adenocarcinoma (≤ 3 cm). METHODS: A total of 528 lung adenocarcinoma patients were enrolled in this retrospective study. Five models were developed for the prediction of thoracic LNM, including PET radiomics, CT radiomics, PET/CT radiomics, clinical and integrated PET/CT radiomics-clinical models. Ten PET/CT radiomics features and two clinical characteristics were selected for the construction of the integrated PET/CT radiomics-clinical model. The predictive performance of all models was examined by receiver operating characteristic (ROC) curve analysis, and clinical utility was validated by nomogram analysis and decision curve analysis (DCA). RESULTS: According to ROC curve analysis, the integrated PET/CT molecular radiomics-clinical model outperformed the clinical model and the three other radiomics models, and the area under the curve (AUC) values of the integrated model were 0.95 (95% CI: 0.93-0.97) in the training group and 0.94 (95% CI: 0.89-0.97) in the test group. The nomogram analysis and DCA confirmed the clinical application value of this integrated model in predicting thoracic LNM. CONCLUSIONS: The integrated PET/CT molecular radiomics-clinical model proposed in this study can ensure a higher level of accuracy in predicting the thoracic LNM of clinical invasive lung adenocarcinoma (≤ 3 cm) compared with the radiomics model or clinical model alone.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Chang C, Ruan M, Lei B, et al. Development of a PET/CT molecular radiomics-clinical model to predict thoracic lymph node metastasis of invasive lung adenocarcinoma ≤ 3 cm in diameter. EJNMMI Res. 2022. PMID: 35445899. doi:10.1186/s13550-022-00895-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。